Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality.

ABSTRACT:

Importance

To our knowledge, this multicenter analysis is the first to test and validate (1) the prognostic impact of comorbidities on 1-year mortality after initial therapy of acute myeloid leukemia (AML) and (2) a novel, risk-stratifying composite model incorporating comorbidities, age, and cytogenetic and molecular risks.

Objective

To accurately estimate risks of mortality by developing and validating a composite model that combines the most significant patient-specific and AML-specific features.

Design, setting, and participants

This is a retrospective cohort study. A series of comorbidities, including those already incorporated into the hematopoietic cell transplantation–comorbidity index (HCT-CI), were evaluated. Patients were randomly divided into a training se

SUBMITTER: Sorror ML 

PROVIDER: S-EPMC5824273 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature